Triple
T10292275
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | human adenovirus serotype 26 |
E241391
|
entity |
| Predicate | hasSynonym |
P3575
|
FINISHED |
| Object | HAdV-26 |
E241391
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: HAdV-26 | Statement: [human adenovirus serotype 26, hasSynonym, HAdV-26]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: HAdV-26 Context triple: [human adenovirus serotype 26, hasSynonym, HAdV-26]
-
A.
human adenovirus serotype 26 (Ad26)
chosen
Human adenovirus serotype 26 (Ad26) is a non-replicating viral vector commonly used in vaccine development to deliver genetic material encoding target antigens and stimulate an immune response.
-
B.
Ad26.COV2.S
Ad26.COV2.S is a single-dose, adenovirus vector-based COVID-19 vaccine developed by Janssen (Johnson & Johnson) to provide protection against SARS-CoV-2 infection.
-
C.
John Cunningham virus
John Cunningham virus is a human polyomavirus that typically remains latent but can cause the severe demyelinating brain disease progressive multifocal leukoencephalopathy in immunocompromised individuals.
-
D.
JC virus
JC virus is a human polyomavirus that typically causes asymptomatic infection but can lead to severe demyelinating brain disease in immunocompromised individuals.
-
E.
Leqembi
Leqembi is an Alzheimer’s disease drug (lecanemab) that targets amyloid-beta plaques to slow cognitive decline in early-stage patients.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d71d1465e88190aaa8b295df3f9c8c |
completed | April 9, 2026, 3:29 a.m. |
Created at: April 6, 2026, 11:42 a.m.